Holen Sie sich die Stockscreener-App
7.60
1.20%
0.09
Handel nachbörslich:
7.64
0.04
+0.53%
Schlusskurs vom Vortag:
$7.51
Offen:
$7.27
24-Stunden-Volumen:
354.62K
Relative Volume:
1.62
Marktkapitalisierung:
$442.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-38.61M
KGV:
-7.6636
EPS:
-0.9917
Netto-Cashflow:
$-29.20M
1W Leistung:
+1.33%
1M Leistung:
-6.40%
6M Leistung:
+27.52%
1J Leistung:
+89.04%
1-Tages-Spanne:
$7.25
$7.69
1-Wochen-Bereich:
$7.175
$7.97
52-Wochen-Spanne:
$2.6801
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Firmenname
Eupraxia Pharmaceuticals Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare EPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
7.60 | 437.50M | 0 | -38.61M | -29.20M | -0.9917 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-16 | Eingeleitet | Canaccord Genuity | Speculative Buy |
| 2025-02-21 | Eingeleitet | Craig Hallum | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Aktie (EPRX) Neueste Nachrichten
You need to know this Canadian biotech stock, analyst says - Cantech Letter
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Announces Earnings Results, Misses Estimates By $0.21 EPS - MarketBeat
Lifesci Capital Has Negative Outlook of EPRX FY2026 Earnings - MarketBeat
What is HC Wainwright's Estimate for EPRX Q1 Earnings? - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Rating Lowered by Zacks Research - MarketBeat
Profit Recap: Will Eupraxia Pharmaceuticals Inc stock hit new highs in YEAR2026 Market WrapUp & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Q2 Earnings Estimate for EPRX Issued By HC Wainwright - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Given New $11.00 Price Target at HC Wainwright - Defense World
EPRX stock on retail radar after strong remission data in digestive disease trial - MSN
Buyout Rumor: Whats BioXcel Therapeutics Incs historical return2026 Trade Ideas & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis - Investing News Network
H.C. Wainwright cuts Eupraxia Pharmaceuticals price target on higher costs - Investing.com
Eupraxia Pharmaceuticals Inc. - Baystreet.ca
HC Wainwright Has Lowered Expectations for Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price - MarketBeat
EPRX Stock On Retail Radar After Strong Remission Data In Digestive Disease Trial - Asianet Newsable
A Little-Known Biotech Is Gaining Retail Buzz With Its Latest Trial Data - Stocktwits
Eupraxia Pharmaceuticals Posts Strong Six-Month EoE Data for EP-104GI as RESOLVE Trial Advances - TipRanks
New Eupraxia data: EoE patients keep symptom relief for 24 weeks - Stock Titan
Freedman lifts Eupraxia (EPRX) stake to 9% after 2026 share purchases - Stock Titan
Aug Reactions: Is Eupraxia Pharmaceuticals Inc affected by consumer sentiment2026 Reactions & Community Consensus Trade Signals - baoquankhu1.vn
Short Interest in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Rises By 19.4% - MarketBeat
Ally Bridge Group NY LLC Buys New Shares in Eupraxia Pharmaceuticals Inc. $EPRX - MarketBeat
(EPRX) Technical Data (EPRX:CA) - Stock Traders Daily
Cantor Fitzgerald Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX) - The Globe and Mail
Eupraxia Pharmaceuticals (NASDAQ: EPRX) files 2025 Form 40-F with audited statements - Stock Titan
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results - Sahm
Eupraxia Widens Q4 Loss but Extends Cash Runway With $63 Million Financing - TipRanks
Eupraxia testing EoE drug extends cash runway to 2028 - Stock Titan
How the (EPRX.WT.A) price action is used to our Advantage - Stock Traders Daily
(EPRX) Market Insights and Trading Signals (EPRX:CA) - Stock Traders Daily
Canadian Investment Regulatory Organization Trading HaltEPRX.WT - marketscreener.com
Eupraxia Pharmaceuticals stock rating reiterated at Raymond James By Investing.com - Investing.com Canada
(EPRX) Stock Analysis and Trading Signals (EPRX:CA) - Stock Traders Daily
(EPRX.WT.A) Optimized Trading Opportunities - Stock Traders Daily
Eupraxia Pharmaceuticals Raises US$63.2 Million in February 2026 Equity Offering to Advance GI Pipeline - TipRanks
Eupraxia (EPRX) raises $63.2M to fund EP-104GI and GI pipeline - Stock Titan
Aug Patterns: Whats the beta of Eupraxia Pharmaceuticals Inc stockGDP Growth & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
(EPRX.WT.A) Trading Strategy and Analysis - Stock Traders Daily
Eupraxia Pharmaceuticals Closes US$63.2 Million Public Offering - Global Legal Chronicle
(EPRX.WT.A) Equity Market Report - Stock Traders Daily
(EPRX) Investment Performance Report (EPRX:CA) - Stock Traders Daily
(EPRX.WT.A) Trading Report (EPRX.WT.A:CA) - Stock Traders Daily
(EPRX) Proactive Strategies (EPRX:CA) - Stock Traders Daily
Bloom Burton initiates Eupraxia stock with buy rating on EoE drug - Investing.com Nigeria
Bloom Burton initiates Eupraxia stock with buy rating on EoE drug By Investing.com - Investing.com Australia
(EPRX.WT.A) Technical Pivots with Risk Controls - Stock Traders Daily
EPRXEupraxia Pharmac Latest Stock News & Market Updates - Stock Titan
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Eupraxia Pharmaceuticals closes $63.2M public offering - Investing.com India
Finanzdaten der Eupraxia Pharmaceuticals Inc-Aktie (EPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.20%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):